Cystic Fibrosis: Management

Cystic fibrosis is an autosomal recessive genetic disorder caused by mutations in the CFTR gene on chromosome 7, most commonly the ΔF508 mutation. This mutation prevents the cystic fibrosis transmembrane conductance regulator protein from functioning properly, resulting in thicker mucus secretions that obstruct the lungs, sinuses, and other organs. CF primarily affects individuals of Northern European descent, occurring at a rate of 1 in 3500.

Airway clearance techniques are critical to daily CF management and include specialized breathing exercises, coughing techniques, and therapy vests that loosen mucus in the lungs. These methods make it easier to cough up and expel thick secretions. Regular exercise is also encouraged as it helps clear mucus from the lungs and improves overall lung function in CF patients.

CF treatment uses multiple medication classes: antibiotics control respiratory infections, bronchodilators widen airways to ease breathing, and mucus thinners liquefy thick secretions for easier clearance. CFTR modulator therapies like ivacaftor and lumacaftor improve faulty CFTR protein function, reducing mucus thickness. Dornase alfa breaks down extracellular DNA to reduce sputum viscosity and elasticity.

CFTR modulator therapies such as ivacaftor and lumacaftor correct the faulty CFTR protein by improving its function and helping balance chloride and sodium in cells. This reduces the thickness of mucus secretions, making them easier to clear from the lungs. These medications represent a newer class of drugs that directly target the underlying genetic defect rather than just managing symptoms.

Dornase alfa, also known as pulmozyme, is a recombinant human deoxyribonuclease I medication that reduces the viscosity and elasticity of purulent sputum by breaking down extracellular DNA. This enzymatic action makes the thick, sticky mucus thinner and easier to clear from the airways, improving airway clearance and lung function in CF patients.

A high-calorie diet is recommended to combat chronic inflammation and malnutrition associated with CF. Regular exercise helps clear mucus from the lungs and improves overall lung function. Pulmonary function testing, including spirometry, is crucial for evaluating and monitoring CF progression, allowing healthcare providers to adjust treatment strategies as needed.

In advanced cases of CF-related lung and liver disease, lung and liver transplants may be considered as major surgical procedures. Though these interventions carry considerable risks, they can potentially extend life and improve quality of life for patients with severe CF who have exhausted medical management options.